OR WAIT 15 SECS
Boston, MA - Although physicians and nurses are familiar with, and comfortable discussing, clinical trials, they refer a mere fraction of their patients for these studies, reflecting, in part, a failure by sponsors, contract research organizations, and investigative site personnel to engage health care providers as partners in the clinical research process, according to a recently completed analysis conducted by the Tufts Center for the Study of Drug Development.
The study, based on a survey of 2,000 physicians and nurses primarily in the United States and Europe, found that nearly all physicians (90%), and the majority of nurses (70%) feel 'somewhat' or 'very' comfortable providing and discussing clinical trial information with their patients, but physicians refer less than 0.2% of their patients into clinical trials, and nurses refer even fewer.
According to Ken Getz, associate professor and director of sponsored research at Tufts CSDD, who led the study, lack of familiarity and comfort level with referring patients into clinical trials on the part of physicians and nurses are often cited to explain low referral rates. However, he noted, the study results show that these factors are playing a much smaller role.
"The study results challenge the long-held notion that health care providers are a barrier to recruitment, and suggest opportunities to rethink and leverage the role of health care providers as facilitators and critical partners in engaging patients before and during clinical trial participation," said Getz.
Key survey findings, reported in the January/February Tufts CSDD Impact Report, released today, include the following:
About The Tufts Center for the Study of Drug Development
The Tufts Center for the Study of Drug Development at Tufts University provides strategic information to help drug developers, regulators, and policy makers improve the quality and efficiency of pharmaceutical development, review, and utilization. Tufts CSDD, based in Boston, conducts a wide range of in-depth analyses on pharmaceutical issues and hosts symposia, workshops, and public forums, and publishes Tufts CSDD Impact Reports, a bi-monthly newsletter providing analysis and insight into critical drug development issues.